Loading cancer entity…
Loading cancer entity…
Clinical trials
6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,044)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07524257 | Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC | withdrawn | Phase 3 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Jun 22, 2026 | clinicaltrials |
| NCT06093503 | Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein | withdrawn | Phase 3 | 0 | AbbVieINDUSTRY |
| 0 |
| Jun 26, 2024 |
| clinicaltrials |
| NCT05791097 | Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.(AdvanTIG-306) | withdrawn | Phase 3 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Jul 24, 2023 | clinicaltrials |
| NCT04466917 | A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 3 | 0 | AmgenINDUSTRY | 0 | Jul 3, 2023 | clinicaltrials |
| NCT00576225 | CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL | withdrawn | Phase 3 | 0 | CTI BioPharmaINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04203511 | INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301) | withdrawn | Phase 3 | 0 | Incyte CorporationINDUSTRY | 0 | Jun 9, 2020 | clinicaltrials |
| NCT03529084 | Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations | withdrawn | Phase 3 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Nov 22, 2019 | clinicaltrials |
| NCT03346304 | Photodynamic Therapy for the Prevention of Lung Cancer(PEARL) | withdrawn | Phase 2 / Phase 3 | 0 | University College, LondonOTHER | 0 | Feb 1, 2019 | clinicaltrials |
| NCT03048136 | A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer(CheckMate 955) | withdrawn | Phase 3 | 0 | Bristol-Myers SquibbINDUSTRY | 5 | Apr 17, 2018 | clinicaltrials |
| NCT02795884 | Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation | withdrawn | Phase 3 | 0 | Yonsei UniversityOTHER | 0 | Dec 30, 2016 | clinicaltrials |
| NCT01058902 | The Effect Of Aspirin On Survival in Lung Cancer | withdrawn | Phase 3 | 0 | Liverpool Heart and Chest Hospital NHS Foundation TrustOTHER | 1 | Mar 7, 2016 | clinicaltrials |
| NCT00907504 | Study Of The Effect Of CP-751,871 In Combination With Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer(ADVIGO1017) | withdrawn | Phase 3 | 0 | PfizerINDUSTRY | 0 | Jun 17, 2014 | clinicaltrials |
| NCT00090675 | Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer(IMAC/Herbst) | withdrawn | Phase 3 | 0 | AstraZenecaINDUSTRY | 0 | Jan 29, 2013 | clinicaltrials |
| NCT00329472 | Efficacy Study of Induction Chemotherapy Before Surgery in Operable Non-small Cell Lung Cancer | withdrawn | Phase 3 | 0 | Samsung Medical CenterOTHER | 0 | Aug 27, 2010 | clinicaltrials |
Data updated 22 days agoSource updated Jun 22, 2026source: clinicaltrials